Skip to content
Triangle logo TriangleGet started
← Study library

NCT03338972 · REGISTRY CONDITION SEARCH

Immunotherapy With BCMA CAR-T Cells in Treating Patients With BCMA Positive Relapsed or Refractory Multiple Myeloma

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE1
Status at capture
COMPLETED
Registry last update
2023-09-08

This phase I trial studies the side effects and best dose of BCMA CAR-T cells in treating patients with BCMA positive multiple myeloma that has come back or does not respond to treatment. T cells are a type of white blood cell and a major component of the immune system. T-cells that have been genetically modified in the laboratory express BCMA and may kill cancer cells with the protein BCMA on their surface. Giving chemotherapy before BCMA CAR-T cells may reduce the amount of disease and to cause a low lymphocyte (white blood cell) count in the blood, which may help the infused BCMA CAR-T cells survive and expand.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Dose-limiting Toxicities (DLT) Rate

→

outcome · POSTED

Count of Patients That Experienced Adverse Events

→

outcome · POSTED

Duration of Persistence of Adoptively Transferred BCMA CAR-T Cells

→

outcome · POSTED

Number of Participants With Detectable BCMA CART Cell Migration to Primary Disease Site (Bone Marrow) at Day 28

→

outcome · POSTED

Objective Response Rate (ORR)

→

outcome · POSTED

Progression-free Survival (PFS)

→

outcome · POSTED

Overall Survival (OS)

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * Have the capacity to give informed consent * Eastern Cooperative Oncology Group (ECOG) performance status score =\< 2. * Have measurable disease by International Myeloma Working Group (IMWG) criteria based on one or more of the following findings: * Serum M-protein \>= 1 g/dL * Urine M-protein \>= 200 mg/24 hour * Involved serum free light chain (sFLC) level \>= 10 mg/dL with abnormal kappa/lambda ratio * Measurable biopsy-proven plasmacytomas (\>= 1 lesion that has a single diameter \>= 2 cm) * Bone marrow plasma cells \>= 30% * Have a diagnosis of BCMA+ MM (\>= 5% BCMA+ by flow cytometry on CD138 co-expressing plasma cells obtained within 45 days of study enrollment); the MM diagnosis must be confirmed by internal pathology review of a fresh biopsy specimen at the Fred Hutchinson Cancer Research Center (FHCRC)/Seattle Cancer Care Alliance (SCCA) * Have relapsed or treatment refractory disease with \>= 10% CD138+ malignant plasma cells (IHC) on BM core biopsy, either: * Following autologous stem cell transplant (ASCT) * Or, if a patient has not yet undergone ASCT, the individual must: * Be transplant ineligible, due to age, comorbidity, patient choice, insurance reasons, concerns of rapidly progressive disease, and/or discretion of attending physician and principal investigator and, * Demonstrate disease that persists after \> 4 cycles of induction therapy and that is double refractory (persistence/progression) after therapy with both a proteasome inhibitor and immunomodulatory drug (IMiD) administered either in tandem, or in sequence; \> 4 cycles of therapy are not required for patients with a diagnosis of plasma cell leukemia * Patients receiving retreatment do not need to meet the \> 10% CD138+ malignant plasma cells (immunohistochemistry staining method \[IHC\]) on BM core biopsy * Male and female patients of reproductive potential must be willing to use an effect contraceptive method before, during, and for at least 4 months after the CAR T cell infusion Exclusion Criteria: * History of another primary malignancy that requires intervention beyond surveillance or that has not been in remission for at least 1 year (the following are exempt from the 1 year limit: non-melanoma skin cancer, curatively treated localized prostate cancer, and cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion on papanicolaou \[PAP\] smear) * Active hepatitis B, hepatitis C at the time of screening * Patients who are (human immunodeficiency virus \[HIV\]) seropositive * Subjects with uncontrolled active infection * \> 1 hospital admission (lasting 5 days or more) for documented infection in prior 6 months * Presence of acute or chronic graft-versus-host disease (GVHD) requiring active treatment unless limited to skin involvement and managed with topical steroid therapy alone * History of any one of the following cardiovascular conditions within the past 6 months: Class III or IV heart failure as defined by the New York Heart Association (NYHA), cardiac angioplasty or stenting, myocardial infarction, unstable angina, or other clinically significant cardiac disease as determined by the principal investigator (PI) or designee * History of clinically relevant or active central nervous system (CNS) pathology such as epilepsy, seizure, paresis, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis, active central nervous system MM involvement and/or carcinomatous meningitis; subjects with previously treated central nervous systems involvement may participate, provided they are free of disease in the CNS (documented by flow cytometry performed on the cerebrospinal fluid \[CSF\] within 14 days of enrollment) and have no evidence of new sites of CNS activity * Pregnant or breastfeeding females * Allogeneic HSCT or donor lymphocyte infusion within 90 days of leukapheresis. * Use of any of the following: * Therapeutic doses of corticosteroids (defined as \> 20 mg/day prednisone or equivalent) within 7 days prior to leukapheresis; physiologic replacement, topical, and inhaled steroids are permitted * Cytotoxic chemotherapeutic agents within 1 week of leukapheresis; oral chemotherapeutic agents are allowed if at least 3 half-lives have elapsed prior to leukapheresis * Lymphotoxic chemotherapeutic agents within 2 weeks of leukapheresis * Daratumumab (or other anti-CD38 therapy) within 30 days of leukapheresis * Experimental agents within 4 weeks of leukapheresis unless progression is documented on therapy and at least 3 half-lives have elapsed prior to leukapheresis * Absolute neutrophil count (ANC) \< 1000/mm\^3, or per PI discretion if cytopenia thought to be related to underlying myeloma. * Hemoglobin (Hgb) \< 8 mg/dl, or per PI discretion if cytopenia thought to be related to underlying myeloma. * Platelet count \< 50,000/mm\^3, or per PI discretion if cytopenia thought to be related to underlying myeloma. * Active autoimmune disease requiring immunosuppressive therapy * Major organ dysfunction defined as: * Creatinine clearance \< 20 ml/min * Significant hepatic dysfunction (serum glutamic-oxaloacetic transaminase \[SGOT\] \> 5 x upper limit of normal; bilirubin \> 3.0 mg/dL) * Forced expiratory volume in 1 second (FEV1) of \< 50% predicted or diffusion capacity of the lung for carbon monoxide (DLCO) (corrected) \< 40% (patients with clinically significant pulmonary dysfunction, as determined by medical history and physical exam should undergo pulmonary function testing) * Anticipated survival of \< 3 months * Contraindication to cyclophosphamide or fludarabine chemotherapy * Patients with known AL subtype amyloidosis * Uncontrolled medical, psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol, as judged by the PI; or unwillingness or inability to follow the procedures required in the protocol
healthy Volunteers
false
minimum Age
21 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Patients undergo leukapheresis. Patients then receive cyclophosphamide and fludarabine on days -4 to -2. Beginning to 36-96 days after chemotherapy, patients receive BCMA-specific CAR-expressing T lymphocytes IV over 20-30 minutes on day 0. Patients may receive a second dose of BCMA-specific CAR-expressing T lymphocytes IV with or without additional cytoreductive chemotherapy at the discretion of the principal investigator or their designee (sub-investigator). Arm 1 contains patients treated as dose level 1 (50 x 10\^6 EGFRt cells)
    intervention Names
    1. Biological: Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143
    2. Drug: Cyclophosphamide
    3. Drug: Fludarabine
    4. Procedure: Leukapheresis
    label
    Treatment (chemotherapy, BCMA CAR-T cells) at dose level 1
    type
    EXPERIMENTAL
  2. description
    Patients undergo leukapheresis. Patients then receive cyclophosphamide and fludarabine on days -4 to -2. Beginning to 36-96 days after chemotherapy, patients receive BCMA-specific CAR-expressing T lymphocytes IV over 20-30 minutes on day 0. Patients may receive a second dose of BCMA-specific CAR-expressing T lymphocytes IV with or without additional cytoreductive chemotherapy at the discretion of the principal investigator or their designee (sub-investigator). Arm 2 contains patients treated as dose level 2 (150 x 10\^6 EGFRt cells)
    intervention Names
    1. Biological: Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143
    2. Drug: Cyclophosphamide
    3. Drug: Fludarabine
    4. Procedure: Leukapheresis
    label
    Treatment (chemotherapy, BCMA CAR-T cells) at dose level 2
    type
    EXPERIMENTAL
  3. description
    Patients undergo leukapheresis. Patients then receive cyclophosphamide and fludarabine on days -4 to -2. Beginning to 36-96 days after chemotherapy, patients receive BCMA-specific CAR-expressing T lymphocytes IV over 20-30 minutes on day 0. Patients may receive a second dose of BCMA-specific CAR-expressing T lymphocytes IV with or without additional cytoreductive chemotherapy at the discretion of the principal investigator or their designee (sub-investigator). Arm 3 contains patients treated as dose level 3 (300 x 10\^6 EGFRt cells)
    intervention Names
    1. Biological: Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143
    2. Drug: Cyclophosphamide
    3. Drug: Fludarabine
    4. Procedure: Leukapheresis
    label
    Treatment (chemotherapy, BCMA CAR-T cells) at dose level 3
    type
    EXPERIMENTAL
  4. description
    Patients undergo leukapheresis. Patients then receive cyclophosphamide and fludarabine on days -4 to -2. Beginning to 36-96 days after chemotherapy, patients receive BCMA-specific CAR-expressing T lymphocytes IV over 20-30 minutes on day 0. Patients may receive a second dose of BCMA-specific CAR-expressing T lymphocytes IV with or without additional cytoreductive chemotherapy at the discretion of the principal investigator or their designee (sub-investigator). Arm 4 contains patients treated as dose level 4 (450 x 10\^6 EGFRt cells)
    intervention Names
    1. Biological: Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143
    2. Drug: Cyclophosphamide
    3. Drug: Fludarabine
    4. Procedure: Leukapheresis
    label
    Treatment (chemotherapy, BCMA CAR-T cells) at dose level 4
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Treatment (chemotherapy, BCMA CAR-T cells) at dose level 1
    2. Treatment (chemotherapy, BCMA CAR-T cells) at dose level 2
    3. Treatment (chemotherapy, BCMA CAR-T cells) at dose level 3
    4. Treatment (chemotherapy, BCMA CAR-T cells) at dose level 4
    description
    Given IV
    name
    Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143
    other Names
    1. Autologous Anti-BCMA-CAR CD4+/CD8+ Cells
    2. Autologous Anti-BCMA-CAR-expressing CD8+ and CD4+ T-lymphocytes
    3. BCMA CAR-CD4+/CD8+ T-cells
    4. BCMA-specific CAR-expressing CD4+/CD8+ T-lymphocytes
    5. FCARH143
    type
    BIOLOGICAL
  2. arm Group Labels
    1. Treatment (chemotherapy, BCMA CAR-T cells) at dose level 1
    2. Treatment (chemotherapy, BCMA CAR-T cells) at dose level 2
    3. Treatment (chemotherapy, BCMA CAR-T cells) at dose level 3
    4. Treatment (chemotherapy, BCMA CAR-T cells) at dose level 4
    description
    Given IV
    name
    Cyclophosphamide
    other Names
    1. (-)-Cyclophosphamide
    2. 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate
    3. Carloxan
    4. Ciclofosfamida
    5. Ciclofosfamide
    6. Cicloxal
    7. Clafen
    8. Claphene
    9. CP monohydrate
    10. CTX
    11. CYCLO-cell
    12. Cycloblastin
    type
    DRUG
  3. arm Group Labels
    1. Treatment (chemotherapy, BCMA CAR-T cells) at dose level 1
    2. Treatment (chemotherapy, BCMA CAR-T cells) at dose level 2
    3. Treatment (chemotherapy, BCMA CAR-T cells) at dose level 3
    4. Treatment (chemotherapy, BCMA CAR-T cells) at dose level 4
    description
    Given IV
    name
    Fludarabine
    other Names
    1. Fluradosa
    type
    DRUG
  4. arm Group Labels
    1. Treatment (chemotherapy, BCMA CAR-T cells) at dose level 1
    2. Treatment (chemotherapy, BCMA CAR-T cells) at dose level 2
    3. Treatment (chemotherapy, BCMA CAR-T cells) at dose level 3
    4. Treatment (chemotherapy, BCMA CAR-T cells) at dose level 4
    description
    Undergo leukapheresis
    name
    Leukapheresis
    other Names
    1. Leukocytopheresis
    2. Therapeutic Leukopheresis
    type
    PROCEDURE
Study design
allocation
NON_RANDOMIZED
intervention Model
SINGLE_GROUP
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
28
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    Observed DLT rates will be summarized based on the DLT-Evaluable analysis set. Outcome will be reported as count of participants in each arm who experienced a DLT. No patients received more than one CAR T cell infusion, so DLT assessment period was only 28 days after first and only CAR T infusion for all patients.
    measure
    Dose-limiting Toxicities (DLT) Rate
    time Frame
    Up to 28 days after CAR T cell infusion
  2. description
    Toxicity graded using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 No patients received more than one CAR T cell infusion, so AE assessment period was only 28 days after first and only CAR T infusion for all patients.
    measure
    Count of Patients That Experienced Adverse Events
    time Frame
    Up to 28 days after CAR T-cell infusion
secondary Outcomes
  1. description
    Persistence of CART cells is tested by qPCR in PBMC.
    measure
    Duration of Persistence of Adoptively Transferred BCMA CAR-T Cells
    time Frame
    Assessed from Baseline up to a maximum of 537 days
  2. measure
    Number of Participants With Detectable BCMA CART Cell Migration to Primary Disease Site (Bone Marrow) at Day 28
    time Frame
    Baseline up to Day 28
  3. description
    Number of patients with a best response of either complete response, stringent complete response, very good partial response or partial response, assessed using modified International Myeloma Working group response criteria.
    measure
    Objective Response Rate (ORR)
    time Frame
    Baseline up to 3 months after CART infusion
  4. description
    Outcome is reported as the count of participants who were alive at the 1 year post treatment mark and did not experience disease progression by the 1 year post treatment mark.
    measure
    Progression-free Survival (PFS)
    time Frame
    Assessed up to 1 year after CART infusion
  5. description
    Outcome is reported as a count of participants who were alive at the 1 year post-infusion timepoint.
    measure
    Overall Survival (OS)
    time Frame
    Assessed up to 1 year after CART infusion
Full study description
brief Summary
This phase I trial studies the side effects and best dose of BCMA CAR-T cells in treating patients with BCMA positive multiple myeloma that has come back or does not respond to treatment. T cells are a type of white blood cell and a major component of the immune system. T-cells that have been genetically modified in the laboratory express BCMA and may kill cancer cells with the protein BCMA on their surface. Giving chemotherapy before BCMA CAR-T cells may reduce the amount of disease and to cause a low lymphocyte (white blood cell) count in the blood, which may help the infused BCMA CAR-T cells survive and expand.
detailed Description
PRIMARY OBJECTIVE: I. To evaluate the safety of adoptive therapy with ex vivo expanded autologous CD8+ plus CD4+ T cells transduced to express a human B cell maturation antigen (BCMA)-targeting chimeric antigen receptor (CAR) for patients with relapsed or treatment refractory multiple myeloma. SECONDARY OBJECTIVES: I. To determine the duration of in vivo persistence and the phenotype of long lived CAR-T cells. II. To determine the degree to which adoptively transferred T cells traffic to multiple myeloma (MM) cells in the bone marrow (BM) and function in vivo. III. To estimate the antitumor activity of adoptively transferred BCMA-specific CAR-expressing T lymphocytes (BCMA CAR-T cells). OUTLINE: This is a dose-escalation study of BCMA-specific CAR-expressing T lymphocytes. Patients undergo leukapheresis to obtain their immune cells, from which CAR-T cells are produced. A few weeks later, patients then receive cyclophosphamide and fludarabine on days -4 to -2. Beginning 36-96 hours after chemotherapy, patients receive BCMA-specific CAR-expressing T lymphocytes intravenously (IV) over 20-30 minutes on day 0. Patients may receive a second dose of BCMA-specific CAR-expressing T lymphocytes IV with or without additional cytoreductive chemotherapy at the discretion of the principal investigator or their designee (sub-investigator). After completion of study treatment, patients are followed up at 60, 90, 120, 180, and 365 days and then annually up to 15 years.
Source references
references
  1. citation
    Tuazon SA, Portuguese AJ, Pont MJ, Cowan AJ, Cole GO, Sather BD, Song X, Thomas S, Wood BL, Blake M, Works MG, Shadman M, Liang EC, Wu QV, Voutsinas JM, Gooley TA, Turtle CJ, Till BG, Coffey DG, Maloney DG, Riddell SR, Green DJ. A phase 1 trial of fully human BCMA CAR-T therapy for relapsed/refractory multiple myeloma with 5-year follow-up. Blood. 2025 Jul 31;146(5):535-545. doi: 10.1182/blood.2024027681.
    pmid
    40198877
    type
    DERIVED
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-93fa7a0d82ccd532bb76
      requested nct id
      NCT03338972
      primary nct id
      NCT03338972
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      payload sha256
      2d5ff7e22d9a46b4ba223ef38dc519d63df0f9420db5d93455932eaa234aec2f
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-93fa7a0d82ccd532bb76
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT03338972
      occurrences
      1. context exact
        NCT03338972
        end
        11
        exact text
        NCT03338972
        start
        0
      offset unit
      unicode_code_points
      query cond
      Plasma Cell Neoplasms
      query disease state id
      ds-plasma-cell-neoplasms
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
      source file sha256
      2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
      source json pointer
      /studies/231/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      e35b278aecd730551903210fac6650ffd005d1b4ad503d8aaf3f65afbd7d25fd

    Preserved source evidence · Not medical advice